多组学服务市场－全球产业规模、份额、趋势、机会和预测，按服务、类型、应用、最终用户、地区和竞争细分，2020-2030 年预测

2024 年全球多组学服务市场价值为 11.6 亿美元，预计到 2030 年将达到 30.4 亿美元，复合年增长率为 17.39%。随着医疗保健系统、研究机构和製药公司越来越多地采用综合组学方法来满足对精准医疗和个人化医疗解决方案日益增长的需求，全球多组学服务市场正在经历显着扩张。多组学服务结合了基因组学、转录组学、蛋白质组学、代谢组学和表观基因组学，可以全面了解生物系统和疾病机制。这些方法在药物发现、生物标记识别和标靶治疗开发中变得至关重要。慢性病和遗传疾病的日益普及、对先进诊断解决方案的需求不断增长以及学术机构和行业参与者之间的密切合作，正在推动多组学服务的采用。随着次世代定序、质谱和生物资讯技术的进步，这些服务的效率和可扩展性得到了显着提高，使其更容易被多个最终用户部门所使用。

多组学服务市场的成长受到多种因素的推动，包括对精准医疗日益增长的关注、对早期疾病检测的需求以及组学资料在临床决策中日益广泛的应用。製药和生物技术公司正在利用多组学来简化药物开发流程、降低流失率并提高临床试验的成功率。先进的生物资讯平台与人工智慧的融合使得资料解读更加精准，从而在疾病分析和患者分层方面取得了突破。来自政府和私人投资者的策略合作和资金支持正在加速创新并拓展服务格局。此外，伴随诊断的应用日益普及，这得益于标靶治疗的监管批准，进一步催生了对多组学服务的需求，因为这些工具在确定适合特定治疗的患者群体方面发挥着核心作用。

儘管成长前景光明，但市场仍面临可能影响其扩张速度的挑战。多组学研究的高成本，尤其是在整合多个资料集时，对小型机构和新兴经济体的承受能力构成了担忧。资料复杂性和互通性问题仍然是重大障碍，因为大规模组学研究会产生大量资料集，需要复杂的分析工具和熟练的专业人员进行解读。资料隐私方面的担忧以及实验室之间缺乏标准化协议，进一步阻碍了多组学的广泛应用。然而，这些挑战也为创新创造了机会，因为各公司正在开发更具成本效益的平台、基于云端的资料解决方案和整合软体，以简化分析并提高可扩展性。随着生物资讯学、人工智慧和自动化技术的不断进步，市场有望克服其中的许多障碍，为未来几年多组学在医疗保健和研究领域的广泛应用铺平道路。

关键市场驱动因素

复杂疾病研究日益增多

主要市场挑战

多组学技术成本高昂

主要市场趋势

数据整合中的人工智慧和机器学习

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球多组学服务市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按服务（研究服务、数据分析服务）
  • 按类型（单细胞多组学、批量多组学）
  • 按应用（生物标记发现、药物发现与开发、合成生物学、其他）
  • 按最终用户（学术和研究机构、製药和生物技术公司、其他）
  • 按公司分类（2024）
  • 按地区
• 市场地图

第六章：北美多组学服务市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第七章：欧洲多组学服务市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太多组学服务市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 韩国
  • 日本
  • 澳洲

第九章：南美洲多组学服务市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东和非洲多组学服务市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 合併与收购（如有）
• 产品发布（如有）
• 最新动态

第十三章：干扰：衝突、流行病与贸易壁垒

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 15 章：竞争格局

• Sapient Bioanalytics, LLC
• Bio-Techne Corporation
• CD Genomics, Inc.
• RayBiotech, Inc.
• Creative Proteomics, Inc.
• Psomagen, Inc.
• Source BioScience Ltd.
• Persistent Systems Ltd.
• Metware Biotechnology Inc.
• Dalton Bioanalytics, Inc.

第 16 章：策略建议

第17章调查会社について・免责事项

The Global Multiomics Services Market was valued at USD 1.16 Billion in 2024 and is expected to reach USD 3.04 Billion by 2030 with a CAGR of 17.39%. The Global Multiomics Services Market is experiencing significant expansion as healthcare systems, research institutions, and pharmaceutical companies increasingly adopt integrated omics approaches to address the growing need for precision medicine and personalized healthcare solutions. Multiomics services, which combine genomics, transcriptomics, proteomics, metabolomics, and epigenomics, allow for a comprehensive understanding of biological systems and disease mechanisms. These approaches are becoming critical in drug discovery, biomarker identification, and the development of targeted therapies. The growing prevalence of chronic and genetic diseases, rising demand for advanced diagnostic solutions, and strong collaborations between academic institutions and industry players are pushing the adoption of multiomics services. With technological advancements in next-generation sequencing, mass spectrometry, and bioinformatics, the efficiency and scalability of these services have improved significantly, making them more accessible across multiple end-user sectors.

The growth of the multiomics services market is driven by a combination of factors, including the rising focus on precision healthcare, the need for early disease detection, and the increasing use of omics data in clinical decision-making. Pharmaceutical and biotechnology companies are leveraging multiomics to streamline drug development pipelines, reduce attrition rates, and enhance the success of clinical trials. The integration of advanced bioinformatics platforms and artificial intelligence is enabling more accurate data interpretation, leading to breakthroughs in disease profiling and patient stratification. Strategic collaborations and funding support from governments and private investors are accelerating innovation and expanding the service landscape. In addition, the rising adoption of companion diagnostics, driven by regulatory approval for targeted therapies, is further creating demand for multiomics services, as these tools play a central role in identifying the right patient groups for specific treatments.

Despite the promising growth prospects, the market faces challenges that could impact its pace of expansion. High costs associated with multiomics studies, particularly when integrating multiple datasets, pose affordability concerns for smaller institutions and emerging economies. Data complexity and interoperability issues remain significant hurdles, as large-scale omics studies generate massive datasets requiring sophisticated analytical tools and skilled professionals for interpretation. Concerns over data privacy and the lack of standardized protocols across laboratories further complicate widespread adoption. Nonetheless, these challenges also create opportunities for innovation, as companies are developing more cost-efficient platforms, cloud-based data solutions, and integrated software to simplify analysis and improve scalability. With continuous advancements in bioinformatics, artificial intelligence, and automation, the market is expected to overcome many of these barriers, paving the way for widespread adoption of multiomics in healthcare and research over the coming years.

Key Market Drivers

Growing Research in Complex Diseases

Rising research into complex diseases continues to drive strong momentum in the Global Multiomics Services Market. Conditions such as cancer, neurodegenerative diseases, cardiovascular disorders, autoimmune illnesses, and rare genetic syndromes involve multifaceted biological pathways that cannot be fully described by single-layer analyses. By integrating genomics, transcriptomics, proteomics, epigenomics, and metabolomics, multiomics enables an in-depth view of disease mechanisms, facilitating discovery of novel biomarkers and therapeutic targets. For example, in September 2023 the U.S. National Institutes of Health announced a USD 50.3 million investment over five years to establish the Multi-Omics for Health and Disease Consortium, funding diverse disease studies and scalable workflows for integrating complex datasets. This type of strategic support underscores how critical multiomics has become in tackling intricate health challenges.

Pharmaceutical and biotech firms are turning increasingly to multiomics strategies to bolster drug development efforts in complex disease areas. Heterogeneous patient responses and disease subtypes demand precision; multiomics data helps stratify patient groups, predict outcomes, and optimize clinical trial design. This approach reduces failure rates and accelerates time-to-market for new therapies. Integration with advanced bioinformatics and AI accelerates interpretation of massive datasets, empowering accelerated insights in oncology, neurological disorders, chronic and metabolic conditions. Strong interest among healthcare providers and research organizations in these capabilities continues to bolster demand for multiomics services.

Academic institutions, public-private partnerships, and government agencies worldwide are pouring resources into large-scale multiomics projects focused on elucidating complex disease biology. Availability of funding and infrastructure from agencies such as the NIH helps drive cross-disciplinary collaborations. As healthcare shifts toward predictive, preventive, and personalized paradigms, multiomics research is increasingly central to that transition. The combination of governmental funding, technological advances in high-throughput platforms, and growing pharmaceutical and academic demand ensures that the study of complex diseases will remain one of the most significant long-term drivers for the multiomics services market.

Key Market Challenges

High Cost of Multiomics Technologies

The Global Multiomics Services Market faces a significant challenge in the form of the high cost associated with multiomics technologies, which limits widespread adoption across both research and clinical settings. The integration of genomics, transcriptomics, proteomics, metabolomics, and epigenomics requires highly sophisticated platforms, advanced sequencing technologies, and powerful computational infrastructure capable of handling vast datasets. These resources involve substantial investment in specialized equipment, consumables, and reagents, making multiomics studies cost-prohibitive for many institutions and healthcare providers, especially in resource-constrained environments. Beyond infrastructure, the costs are compounded by the need for skilled professionals who can design experiments, manage complex data pipelines, and perform advanced bioinformatics analysis, often driving up operational expenses.

The expense of large-scale projects becomes even more challenging when multiomics data are applied in clinical research or precision medicine, as validation, regulatory compliance, and data interpretation demand additional financial resources. High costs not only limit accessibility for smaller research institutes and hospitals but also restrict broader patient access to personalized diagnostic and therapeutic solutions that multiomics could enable. This creates a divide between well-funded organizations capable of adopting multiomics and those unable to invest at the required scale, slowing the overall pace of market penetration. Addressing cost-related barriers through technological innovations, more affordable sequencing methods, and scalable cloud-based analytics will be crucial for ensuring that multiomics services can transition from niche applications to mainstream use in global healthcare and life sciences.

Key Market Trends

AI and Machine Learning in Data Integration

The integration of artificial intelligence and machine learning into multiomics services is emerging as a transformative trend, addressing one of the most critical challenges in the field, the complexity and scale of multiomics datasets. Genomic, transcriptomic, proteomic, metabolomic, and epigenomic data generate enormous volumes of information that are difficult to analyze through conventional bioinformatics tools. AI-driven platforms are enabling researchers to uncover hidden patterns, correlate molecular profiles, and predict disease biomarkers with a level of precision and speed that was previously unattainable. Machine learning models are increasingly being applied to classify patient subgroups, identify novel therapeutic targets, and support drug discovery pipelines. The adoption of deep learning techniques allows for the integration of heterogeneous datasets, leading to more comprehensive biological insights and accurate disease modeling.

Pharmaceutical and biotechnology companies are investing in AI-powered analytics to streamline clinical trial design, accelerate target validation, and improve patient stratification for personalized therapies. Cloud-based AI solutions are also gaining prominence, offering scalable infrastructure for large-scale data processing while supporting collaboration across research institutions and healthcare organizations. These innovations are reducing data interpretation bottlenecks, improving reproducibility of results, and making multiomics applications more accessible for both research and clinical use. As AI and machine learning continue to evolve, they are expected to play a pivotal role in shaping the future of multiomics services by enabling more efficient integration, predictive modeling, and translation of omics data into actionable healthcare solutions.

Key Market Players

• Sapient Bioanalytics, LLC
• Bio-Techne Corporation
• CD Genomics, Inc.
• RayBiotech, Inc.
• Creative Proteomics, Inc.
• Psomagen, Inc.
• Source BioScience Ltd.
• Persistent Systems Ltd.
• Metware Biotechnology Inc.
• Dalton Bioanalytics, Inc.

Report Scope:

In this report, the Global Multiomics Services Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Multiomics Services Market, By Service:

• Research Services
• Data Analysis Services

Multiomics Services Market, By Type:

• Single-cell Multiomics
• Bulk Multiomics

Multiomics Services Market, By Application:

• Biomarker Discovery
• Drug Discovery & Development
• Synthetic Biology
• Others

Multiomics Services Market, By End User:

• Academic & Research Institutes
• Pharmaceutical and Biotechnology Companies
• Others

Multiomics Services Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Multiomics Services Market.

Available Customizations:

Global Multiomics Services Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Multiomics Services Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Service (Research Services, Data Analysis Services)
  • 5.2.2. By Type (Single-cell Multiomics, Bulk Multiomics)
  • 5.2.3. By Application (Biomarker Discovery, Drug Discovery & Development, Synthetic Biology, Others)
  • 5.2.4. By End User (Academic & Research Institutes, Pharmaceutical and Biotechnology Companies, Others)
  • 5.2.5. By Company (2024)
  • 5.2.6. By Region
• 5.3. Market Map

6. North America Multiomics Services Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Service
  • 6.2.2. By Type
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Multiomics Services Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Service
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Mexico Multiomics Services Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Service
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Canada Multiomics Services Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Service
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Multiomics Services Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Service
  • 7.2.2. By Type
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Multiomics Services Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Service
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. Germany Multiomics Services Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Service
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Multiomics Services Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Service
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Multiomics Services Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Service
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Multiomics Services Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Service
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia-Pacific Multiomics Services Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Service
  • 8.2.2. By Type
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Multiomics Services Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Service
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Multiomics Services Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Service
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. South Korea Multiomics Services Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Service
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. Japan Multiomics Services Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Service
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Multiomics Services Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Service
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. South America Multiomics Services Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Service
  • 9.2.2. By Type
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Multiomics Services Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Service
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Multiomics Services Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Service
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Multiomics Services Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Service
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. Middle East and Africa Multiomics Services Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Service
  • 10.2.2. By Type
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Multiomics Services Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Service
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Multiomics Services Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Service
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Multiomics Services Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Service
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Disruptions: Conflicts, Pandemics and Trade Barriers

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Sapient Bioanalytics, LLC
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Bio-Techne Corporation
• 15.3. CD Genomics, Inc.
• 15.4. RayBiotech, Inc.
• 15.5. Creative Proteomics, Inc.
• 15.6. Psomagen, Inc.
• 15.7. Source BioScience Ltd.
• 15.8. Persistent Systems Ltd.
• 15.9. Metware Biotechnology Inc.
• 15.10. Dalton Bioanalytics, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer